Results 21 to 30 of about 293,272 (302)

Engineering CAR-T cells [PDF]

Biomarker Research, 2017
Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors. CAR-T cells are generated by the T cells from patients' or donors' blood.
Cheng Zhang, Jun Liu, Jiang F. Zhong, Xi Zhang   +3 more
openaire   +3 more sources

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy [PDF]

, 2020
Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor responses in patients with B-cell malignancies. However, clonal kinetics and transcriptional programs that regulate the fate of CAR-T cells after infusion remain poorly ...
Adair, Jennifer E., DeBerg, Hannah A., Enstrom, Mark R., Gersuk, Vivian, Gottardo, Raphaël, Hanafi, Laïla-Aïcha, Hawkins, Reed, Kiem, Hans-Peter, Linsley, Peter S., Maloney, David G., Pande, Dnyanada, Riddell, Stanley R., Sheih, Alyssa, Turtle, Cameron J., Voillet, Valentin, Wohlfahrt, Martin E., Yajima, Masanao   +16 more
core   +1 more source

CAR-T Cell Therapy [PDF]

International Journal of Molecular Sciences, 2020
CAR-T therapy has revolutionized the treatment of select hematological malignancies, namely, acute lymphoblastic leukemia and large B-cell lymphomas [...]
openaire   +2 more sources

Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers

Frontiers in Immunology, 2020
Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell ...
Manuel Gotti, Irene Defrancesco, Mario D’Angelo, Sabrina Basso, Sabrina Basso, Luca Crotto, Alfredo Marinelli, Alfredo Marinelli, Cristina Maccalli, Vincenzo Iaconianni   +9 more
doaj   +1 more source

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

Journal of Experimental & Clinical Cancer Research, 2022
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies.
Kevin Pan, Hizra Farrukh, Veera Chandra Sekhar Reddy Chittepu, Huihong Xu, Chong-xian Pan, Zheng Zhu   +5 more
doaj   +1 more source

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function

Frontiers in Immunology, 2022
The quality of chimeric antigen receptor (CAR)-T cell products, namely, memory and exhaustion markers, affects the long-term functionality of CAR-T cells.
Masaya Suematsu, Shigeki Yagyu, Nobuyoshi Nagao, Susumu Kubota, Yuto Shimizu, Miyuki Tanaka, Yozo Nakazawa, Toshihiko Imamura   +7 more
doaj   +1 more source

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. [PDF]

, 2018
Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of
Avanzi, Mauro P, Brentjens, Renier J, Cheung, Kenneth, Daniyan, Anthony F, Li, Xinghuo, Park, Hyebin, Purdon, Terence J, Spitzer, Matthew H, van Leeuwen, Dayenne G, Wijewarnasuriya, Dinali P, Yeku, Oladapo   +10 more
core   +1 more source

Approved CAR T cell therapies [PDF]

, 2018
Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah™ and Yescarta™) were recently approved by the FDA. Kymriah™ is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute ...
Kros, J.M. (Johan), Li, J. (Jin), Zheng, P.P. (Pingpin)   +2 more
core   +9 more sources

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. [PDF]

, 2014
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages.
Albelda, Steven M., Antzis, Michael, Cotner, Cody E., Durham, Amy C., Johnson, Laura A., June, Carl H., Kapoor, Veena, Lo, Albert, Majumdar, Rajrupa S., Puré, Ellen, Scholler, John, Solomides, MD, Charalambos C., Sun, Jing, Wang, Liang-Chuan S.   +13 more
core   +2 more sources

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing [PDF]

, 2019
BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date.
Andersch, Lena, Eggert, Angelika, Flemmig, Carina, Grunewald, Laura, Henssen, Anton, Jensen, Michael C., Joussen, Antonia, Klaus, Anika, Künkele, Annette, Radke, Josefine, Rossig, Claudia, Schulte, Johannes H., Schumann, Elisa, Schwiebert, Silke, Winkler, Annika, Zirngibl, Felix   +15 more
core   +2 more sources